Sort
10,766 grants matching “checkpoint inhibitor”
Stanford Project 2
$516,569Calvin J Kuo · University Of California, San Francisco · U54 · FY2021 · CA
Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.
$516,407Gordon B. Mills · Oregon Health & Science University · U01 · FY2022 · CA
Acute Kidney Injury and Double Negative T Cells
$516,264Abdel Hamad · Johns Hopkins University · R01 · FY2020 · DK
Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitory Therapy for Cancer
$516,179Andrew Y Koh · Ut Southwestern Medical Center · R01 · FY2023 · CA
Immunogen design and testing
$516,100Barton F Haynes · University Of Pennsylvania · P01 · FY2017 · AI
Targeting ATM to boost systemic effects of radiotherapy and immunotherapy
$516,032Yunyan Jennifer Jennifer Zhang · Duke University · R01 · FY2023 · CA
Targeting ATM to boost systemic effects of radiotherapy and immunotherapy
$516,032Chuan-Yuan Li · Duke University · R01 · FY2022 · CA
The Role of the Y Chromosome in Bladder Tumor Development, Growth And Progression
$515,907Dan Theodorescu · Cedars-Sinai Medical Center · P01 · FY2024 · CA
IDO1 and Immunotolerance in Glioblastoma
$515,890Derek Alan Wainwright · Loyola University Chicago · R01 · FY2023 · NS
Biomarkers and Therapeutic Targets in Angiogenesis and Metastasis
$515,673Rosandra Kaplan · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA
Exploring the Function of MHC-II/Lag3 Axis in Brain Metastasis to Develop Novel Therapeutic Strategies
$515,611Dihua Yu · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Cyclin C-CDK8/19 kinases in development and in cancer
$515,451Piotr Sicinski · Dana-Farber Cancer Inst · R01 · FY2023 · CA
Mechanisms and Functions of ATR signaling
$515,443David K Cortez · Vanderbilt University · R01 · FY2025 · CA
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
$515,359Steven Mark Albelda · University Of Pennsylvania · P01 · FY2020 · CA
Project 2 - Preclinical studies: Overcoming tumor heterogeneity
$515,359Steven Mark Albelda · University Of Pennsylvania · P01 · FY2021 · CA
Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer
$515,141Ming Li · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
$515,091Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Targeting APOBEC3-induced squamous differentiation in bladder cancer
$514,582William Y Kim · Univ Of North Carolina Chapel Hill · R01 · FY2025 · CA
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$514,343Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
Cyclin Dependent Kinases as Epigenetic Therapy Targets
$514,307Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2024 · CA
Development of selective HDAC6 inhibitors to improve cancer immunotherapy
$514,297Alejandro V Villagra · Georgetown University · R01 · FY2022 · CA
Biochemical Studies of Human DNA Polymerase Delta
$514,046New York Medical College · R01 · FY2005 · GM
Project 1: Evaluating stem-like T cells and improving efficacy of checkpoint inhibitors in NSCLC
$513,707Rafi Ahmed · Emory University · P50 · FY2023 · CA
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
$513,659Jindan Yu · Emory University · R01 · FY2025 · CA
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
$513,608Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA